Answers are grounded in this paper and cite their sources.
Identifies colchicine and shikonin as potential therapies for methotrexate-resistant choriocarcinoma, suggesting new treatment options.
Choriocarcinoma is a rare and aggressive form of gestational trophoblastic neoplasia, and methotrexate resistance remains a clinical challenge. In this study, we aimed to identify alternative therapeutic compounds that are effective against methotrexate-resistant choriocarcinoma by screening a drug library. Methotrexate-resistant JAR and JEG-3 cell lines were established by stepwise exposure to increasing concentrations of methotrexate. RNA sequencing confirmed increased expression of DHFR in the methotrexate-resistant JAR cells compared with the parental cells; however, gene silencing of DHFR mRNA did not sufficiently restore methotrexate sensitivity. Then, a two-step in vitro screening was conducted using a drug library consisting of more than 1000 compounds. In the primary screen, fifty-five compounds exhibited reduced cell viability to less than 25% in both cell lines. Based on known pharmacological classifications, 19 compounds were selected for secondary screening. Of these, colchicine and shikonin showed relatively higher cytotoxicity in both methotrexate-resistant cell lines. In vivo experiments showed a trend toward reduced tumor volume with shikonin and a longer time to the predefined study endpoint, whereas colchicine exhibited more limited antitumor activity. In conclusion, colchicine and shikonin demonstrated antitumor activity against methotrexate-resistant choriocarcinoma and warrant further investigation as potential therapeutic candidates.
No takes yet. Share an insight, caveat, or question.
Nishiko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: